Podoplanin-Positive Cancer-Associated Fibroblasts in the Tumor Microenvironment Induce Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma with EGFR Mutation

被引:102
作者
Yoshida, Tatsuya [1 ,2 ,3 ]
Ishii, Genichiro [1 ]
Goto, Koichi [2 ]
Neri, Shinya [1 ]
Hashimoto, Hiroko [1 ]
Yoh, Kiyotaka [2 ]
Niho, Seiji [2 ]
Umemura, Shigeki [2 ]
Matsumoto, Shingo [2 ]
Ohmatsu, Hironobu [2 ]
Iida, Shinsuke [3 ]
Niimi, Akio [3 ]
Nagai, Kanji [2 ]
Ohe, Yuichiro [2 ]
Ochiai, Atsushi [1 ]
机构
[1] Natl Canc Ctr Hosp East, Div Pathol, Res Ctr Innovat Oncol, Kashiwa, Chiba 2778577, Japan
[2] Natl Canc Ctr Hosp East, Div Thorac Oncol, Kashiwa, Chiba 2778577, Japan
[3] Nagoya City Univ, Grad Sch Med Sci, Dept Med Oncol & Immunol, Nagoya, Aichi, Japan
关键词
TYROSINE KINASE INHIBITORS; PREDICTS POOR-PROGNOSIS; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; OPEN-LABEL; GEFITINIB; GROWTH; CHEMOTHERAPY; STROMA; POLYMORPHISM;
D O I
10.1158/1078-0432.CCR-14-0846
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The biologic characteristics of microenvironmental constituents, especially cancer-associated fibroblasts (CAF), can be key regulators of the cellular sensitivity to molecular-targeted therapy. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) have marked therapeutic effects against non-small cell lung cancer (NSCLC) with EGFR mutations, but some patients have exhibited primary resistance to EGFR-TKIs. We recently reported that podoplanin-positive fibroblasts are associated with a tumor-promoting phenotype of CAFs in lung adenocarcinoma. The aim of this study was to evaluate whether the susceptibility of NSCLC to EGFR-TKIs could be affected by podoplanin-expressing CAFs. Experimental Design: We evaluated the EGFR-TKI sensitivity of EGFR-mutant lung adenocarcinoma cell lines cocultured with podoplanin-expressing CAFs. We also examined the association between the expression of podoplanin in CAFs in surgical specimens and EGFR-TKI response of postoperative recurrent patients with EGFR mutations (N = 106). Results: Lung adenocarcinoma cell lines became more resistant to EGFR-TKI when cocultured with podoplanin-expressing CAFs, compared with control CAFs in vitro. The knockdown of podoplanin expression on CAFs cancelled the resistance to EGFR-TKIs in cancer cells. Compared with control CAFs, the cancer cells that were cocultured with podoplanin-positive CAFs continued to exhibit significantly higher p-ERK levels after treatment with gefitinib. Furthermore, postoperative recurrent patients with podoplanin-positive CAFs had a significantly lower overall response rate to EGFR-TKIs compared with those with podoplanin-negative CAFs (53% vs. 83%; P < 0.01). Conclusions: Podoplanin-positive CAFs play an important role in primary resistance to EGFR-TKIs and may be an ideal therapeutic target for use in combination therapy with EGFR-TKIs. (C) 2014 AACR.
引用
收藏
页码:642 / 651
页数:10
相关论文
共 50 条
[41]   Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation [J].
Miyashita, Yosuke ;
Ko, Ryo ;
Shimada, Naoko ;
Mitsuishi, Yoichiro ;
Miura, Keita ;
Matsumoto, Naohisa ;
Asao, Tetsuhiko ;
Shukuya, Takehito ;
Shibayama, Rina ;
Koyama, Ryo ;
Takahashi, Kazuhisa .
THORACIC CANCER, 2021, 12 (03) :329-338
[42]   Optimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network meta-analysis [J].
Zhang, Yaxiong ;
Sheng, Jin ;
Yang, Yunpeng ;
Fang, Wenfeng ;
Kang, Shiyang ;
He, Yang ;
Hong, Shaodong ;
Zhan, Jianhua ;
Zhao, Yuanyuan ;
Xue, Cong ;
Ma, Yuxiang ;
Zhou, Ting ;
Ma, Shuxiang ;
Gao, Fangfang ;
Qin, Tao ;
Hu, Zhihuang ;
Tian, Ying ;
Hou, Xue ;
Huang, Yan ;
Zhou, Ningning ;
Zhao, Hongyun ;
Zhang, Li .
ONCOTARGET, 2016, 7 (15) :20093-20108
[43]   EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance [J].
Fogli, Stefano ;
Polini, Beatrice ;
Del Re, Marzia ;
Petrini, Iacopo ;
Passaro, Antonio ;
Crucitta, Stefania ;
Rofi, Eleonora ;
Danesi, Romano .
PHARMACOGENOMICS, 2018, 19 (08) :727-740
[44]   Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance [J].
Wang, Ying ;
Liu, Qiuyun ;
Chen, Haojie ;
You, Jun ;
Peng, Bin ;
Cao, Fanfan ;
Zhang, Xue ;
Chen, Qing ;
Uzan, Georges ;
Xu, Limin ;
Zhang, Denghai .
ANTI-CANCER DRUGS, 2018, 29 (08) :748-755
[45]   GSTO1 aggravates EGFR-TKIs resistance and tumor metastasis via deglutathionylation of NPM1 in lung adenocarcinoma [J].
Shen, Ning-xiang ;
Luo, Ming-yu ;
Gu, Wei-ming ;
Gong, Miaomiao ;
Lei, Hui-min ;
Bi, Ling ;
Wang, Cheng ;
Zhang, Mo-cong ;
Zhuang, Guanglei ;
Xu, Lu ;
Zhu, Liang ;
Chen, Hong-zhuan ;
Shen, Ying .
ONCOGENE, 2024, 43 (33) :2504-2516
[46]   Organoid culture containing cancer cells and stromal cells reveals that podoplanin-positive cancer-associated fibroblasts enhance proliferation of lung cancer cells [J].
Nakamura, Hiroshi ;
Sugano, Masato ;
Miyashita, Tomoyuki ;
Hashimoto, Hiroko ;
Ochiai, Atsushi ;
Suzuki, Kenji ;
Tsuboi, Masahiro ;
Ishii, Genichiro .
LUNG CANCER, 2019, 134 :100-107
[47]   Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway [J].
Hongyan Wu ;
Fangtian Fan ;
Zhaoguo Liu ;
Cunsi Shen ;
Aiyun Wang ;
Yin Lu .
Cancer Chemotherapy and Pharmacology, 2015, 76 :307-315
[48]   Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance [J].
Tsubata, Yukari ;
Tanino, Ryosuke ;
Isobe, Takeshi .
CELLS, 2021, 10 (11)
[49]   Statins use and its impact in EGFR-TKIs resistance to prolong the survival of lung cancer patients: A Cancer registry cohort study in Taiwan [J].
Nguyen, Phung-Anh ;
Chang, Chih-Cheng ;
Galvin, Cooper J. ;
Wang, Yao-Chin ;
An, Soo Yeon ;
Huang, Chih-Wei ;
Wang, Yu-Hsiang ;
Hsu, Min-Huei ;
Li, Yu-Chuan ;
Yang, Hsuan-Chia .
CANCER SCIENCE, 2020, 111 (08) :2965-2973
[50]   Bufalin Reverses HGF-Induced Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer Cells via Blockage of Met/PI3k/Akt Pathway and Induction of Apoptosis [J].
Kang, Xiao-Hong ;
Xu, Zhen-Ye ;
Gong, Ya-Bin ;
Wang, Li-fang ;
Wang, Zhong-Qi ;
Xu, Ling ;
Cao, Fei ;
Liao, Ming-juan .
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2013, 2013